CD19 and B-cell non-Hodgkin lymphoma: Among the anti-CD19 CAR-T cells, the cell product KYV-101, derived from a fully human, anti-CD19, second-generation CAR construct Hu19-CD828Z, has been associated with decreased cytokine production, which is correlated with a lower risk of cytokine release syndrome (CRS) and reduced neurotoxicity in patients with B-cell lymphoma, according to the data from clinical trial NCT02659943 [97].